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Saleh Yazdani1,*,†, Fariba Poosti2,*,‡, Luis Toro2,3,4, Johannes Wedel2, Rik Mencke2, 
Katarina Mirković1, Martin H. de Borst1, J. Steven Alexander5, Gerjan Navis1, Harry van Goor2, 
Jacob van den Born1 & Jan-Luuk Hillebrands2
Excessive lymphangiogenesis is associated with cancer progression and renal disease. Attenuation of 
lymphangiogenesis might represent a novel strategy to target disease progression although clinically 
approved anti-lymphangiogenic drugs are not available yet. VitaminD(VitD)-deficiency is associated 
with increased cancer risk and chronic kidney disease. Presently, effects of VitD on lymphangiogenesis 
are unknown. Given the apparently protective effects of VitD and the deleterious associations of 
lymphangiogenesis with renal disease, we here tested the hypothesis that VitD has direct anti-
lymphangiogenic effects in vitro and is able to attenuate lymphangiogenesis in vivo. In vitro cultured 
mouse lymphatic endothelial cells (LECs) expressed VitD Receptor (VDR), both on mRNA and protein 
levels. Active VitD (calcitriol) blocked LEC tube formation, reduced LEC proliferation, and induced LEC 
apoptosis. siRNA-mediated VDR knock-down reversed the inhibitory effect of calcitriol on LEC tube 
formation, demonstrating how such inhibition is VDR-dependent. In vivo, proteinuric rats were treated 
with vehicle or paricalcitol for 6 consecutive weeks. Compared with vehicle-treated proteinuric rats, 
paricalcitol showed markedly reduced renal lymphangiogenesis. In conclusion, our data show that VitD 
is anti-lymphangiogenic through VDR-dependent anti-proliferative and pro-apoptotic mechanisms. Our 
findings highlight an important novel function of VitD demonstrating how it may have therapeutic value 
in diseases accompanied by pathological lymphangiogenesis.
In addition to the blood vessels, lymphatic vessels (LVs) also form an integral part of the mammalian vasculature. 
LVs play crucial roles in a variety of vital processes in the body including immune surveillance, regulation of 
tissue fluid balance, lipid absorption and tissue homeostasis1. LVs are also associated with various pathological 
conditions such as inflammation, lymphedema, transplant rejection, hypertension, and tumor metastasis2. In the 
past decade, extensive research has described on the roles and mechanisms of LV function in organ homeostasis, 
both in health and disease3. Evidence from many animal models and clinico-pathological studies clearly support 
the importance of intra-organ LVs, and their outgrowth (i.e., lymphangiogenesis) in several solid organs includ-
ing the kidney4. Renal lymphangiogenesis has been reported to occur in several conditions such as primary renal 
fibrotic diseases, proteinuria, and in renal allografts after transplantation4. Although not yet investigated in renal 
disease, modulating lymphangiogenesis in other organs by either promoting or inhibiting the formation of new 
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LVs has been shown to have therapeutic value. Experimental lymphangiogenic therapy by vascular endothelial 
growth factor-C (VEGF-C) and angiopoietin-2 (ANG-2) restored lymphatic function, improved interstitial fluid 
drainage, and consequently reduced post-surgical lymphedema5. In contrast, inhibiting lymphangiogenesis in 
experimental transplantation models of cornea (by several strategies e.g. anti-vascular endothelial growth fac-
tor receptor 3 (VEGFR3) or anti-VEGF-C antibodies, neuropilin-2 blockade)6–8, heart (adenoviral VEGFR-3-Ig 
(i.e. soluble VEGFR3) and anti-VEGFR3 neutralizing antibody)9 and pancreatic islet (analog of sphingosine 
1-phosphate FTY720, kinase inhibitor Sunitinib, anti-VEGFR3 antibody)10 increased graft survival. Targeting 
lymphangiogenesis has also been suggested to be a useful therapeutic approach in inflammatory11–13 and fibrotic 
diseases14,15, in addition to its well-studied central role in cancer therapy and tumor metastasis16,17. Despite 
numerous studies in this field, no anti-lymphangiogenic drugs have so far been approved for clinical use in these 
conditions.
Vitamin D (VitD) participates in many biological actions in the body, and hence is regarded as “a pleiotropic 
hormone”18. Beyond its cognate function in bone metabolism and calcium homeostasis, “nonclassical” effects of 
VitD have been shown protective in a variety of pathophysiological conditions such as cardiovascular disease, 
cancer and immunity19. These effects have been mostly linked to the expression of VitD Receptor (VDR) in tis-
sues that are not classically involved in calcium homeostasis19. The ability of VitD to modulate the expression of 
genes involved in biological processes such as cell proliferation, apoptosis, oxidative stress, inflammation, matrix 
homeostasis and angiogenesis, makes VitD an attractive candidate therapeutic for cancer and cardiovascular 
diseases20,21. Blood vascular endothelial cells express VDR22 and VitD deficiency has been shown to be associated 
with increased arterial stiffness and endothelial dysfunction, underscoring the importance of VitD for maintain-
ing endothelial health and function23.
Conversely, the data regarding the effect of VitD on angiogenesis is equivocal. Depending on the model, VitD 
analogues have been shown to have no effect on angiogenesis24,25, to have pro-angiogenic effects26, or to have 
anti-angiogenic effects27. However, no data have been reported on the potential effects of VitD on lymphatic 
endothelial cells (LECs) and lymphangiogenesis. The impact of VitD and its analogues on renal pathophysiology 
has been extensively studied28–33. Most of the results from these studies suggest that VitD may be considered a 
generally safe and effective therapeutic in diverse kidney diseases, but the effect of VitD on renal lymphatics and 
lymphangiogenesis has not yet been described.
Given the beneficial effects of VitD treatment in renal disease, and the deleterious associations of lymphang-
iogenesis with renal disease, we here tested the hypothesis that VitD has direct anti-lymphangiogenic effects and 
is able to attenuate lymphangiogenesis.
To address this, we here examined the direct effects of VitD on LEC tube formation, proliferation and apopto-
sis in vitro, and the effects of VitD treatment on lymphangiogenesis in vivo.
Results
Cultured lymphatic endothelial cells (LECs) express VDR. Immunohistochemistry (IHC) was per-
formed to confirm lymphatic endothelial phenotype of cultured cells. As shown in Fig. 1a, compared to the 
negative control staining, LECs expressed Prospero homeobox protein 1 (Prox-1), VEGFR3, and Podoplanin. 
This combination of markers is expressed exclusively by LECs. The presence of VDR protein was confirmed by 
western blotting using anti-VDR antibody D6 (Fig. 1b). Mouse tubular epithelial cells (MTCs) were considered 
positive controls since mouse renal tubular epithelium is known to express VDR34. Western blot results indicate 
that LECs clearly express VDR albeit at lower levels compared with MTCs. Immunofluorescent staining with the 
same antibody confirmed VDR expression in LECs (Fig. 1c).
Calcitriol inhibits tube formation of LECs in a VDR-dependent manner. To investigate a poten-
tial lymphangiostatic effect of calcitriol on LECs, tube formation assays were performed. Interestingly, calcitriol 
appeared to have lymphangiostatic effect, and dose-dependently decreased lymphatic capillary tube formation 
(Fig. 2a). Quantitative analyses expressed as both total tube length (Fig. 2b) and total number of branching points 
(Fig. 2c) revealed reduced tube formation in the presence of calcitriol. These data indicate that the VitD analogue 
calcitriol exerts anti-lymphangiogenic effects in vitro. We next examined whether the observed effects on tube 
formation were VDR-dependent. At mRNA level, qRT-PCR indicated that VDR expression in LECs transfected 
with VDR siRNA was reduced remarkably compared to scramble siRNA knock-down after 48 h (81% and 62% 
reduction compared to scramble in siRNA 1 and siRNA 2, respectively) (Fig. 3a). Immunofluorescent stain-
ing showed that VDR siRNA transfected cells had virtually no VDR protein expression when compared with 
non-transfected and scramble siRNA transfected cells (Fig. 3b). Using VDR and scramble siRNA transfected 
cells in the tube formation assay, we showed that VDR knock-down almost completely abolished the inhibi-
tory effect of calcitriol on tube formation (Fig. 4a). Quantification showed that the significant reduction of tube 
formation induced by calcitriol was abolished by VDR siRNA, both in terms of tube length (Fig. 4b) but also 
numbers of branching points (Fig. 4c). These data indicate that calcitriol-induced impairment of tube formation 
is VDR-dependent.
Effects of calcitriol on LEC proliferation and apoptosis. Next we sought to identify the mechanism 
underlying VitD/VDR-mediated reduction in tube formation, focusing on LEC proliferation and induction of 
apoptosis. We studied the effect of calcitriol on LEC proliferation in vitro using Cell Proliferation Reagent WST-1. 
No effect of calcitriol on proliferation was observed after 24 h incubation (Fig. 5a). However, after 48 h, the lower 
calcitriol concentrations (0.1 nM, 1 nM, and 10 nM) showed a marked increase in proliferation compared with 
control. However, the highest concentration (100 nM), which had a clear inhibitory effect on tube formation, also 
significantly reduced this increase of proliferation to the level of placebo control.
www.nature.com/scientificreports/
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We next analyzed possible induction of apoptosis. To accomplish this, LECs were plated and after 24 h of 
attachment and subsequent 24 h serum starvation, cells were treated with calcitriol (100 nM) or vehicle alone for 
6 h. Untreated cells served as negative control (medium). To detect apoptotic cells staining for Annexin V and 
7-AAD was performed followed by flow cytometry. Apoptotic cells are Annexin V+ 7-AAD−. Figure 5b shows 
representative dot plots of non-treated and calcitriol-treated LECs. Quantitative analysis indicated that 100 nM 
calcitriol induces significant LEC apoptosis (Fig. 5c).
Figure 1. Cultured murine LECs express VDR. To check lymphatic origin of mouse LECs, we used three 
different well-established markers expressed by LECs. (a) Lymphatic origin of murine LECs was confirmed 
by IHC for Prox-1, VEGFR3 and Podoplanin (400x). Scale bar: 50 μ m. (b) VDR expression of in vitro grown 
murine LECs was evaluated by western blot. Murine renal tubular epithelial cells (MTCs) served as positive 
control. (c) VDR expression of murine LECs was assessed by immunofluorescence (antibody D6) staining 
(200x). Scale bar: 50 μ m.
www.nature.com/scientificreports/
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Paricalcitol treatment prevents lymphangiogenesis in vivo. To translate our in vitro findings to the 
in vivo setting, we analyzed whether the VitD analogue paricalcitol is able to attenuate proteinuria-associated 
lymphangiogenesis in a rat model. We previously showed that in the Adriamycin Nephrosis rat model, massive 
lymphangiogenesis occurs between weeks 6 to 12 after induction of disease35. Therefore, we treated animals in this 
time frame with paricalcitol to test whether this can impair adriamycin-induced lymphangiogenesis in the kid-
ney. The results of LV quantification in the kidney of proteinuric rats receiving paricalcitol (160 ng/kg three times 
per week p.o.) showed a significant inhibitory effect on renal lymphangiogenesis compared to vehicle-treated 
proteinuric rats (Fig. 6a,b). This experiment confirms, as a proof of principle, that treatment with a VitD analogue 
is also able to prevent lymphangiogenesis in vivo.
Discussion
The present study reveals an inhibitory effect of vitamin D (VitD) on lymphangiogenesis. The results demon-
strate that in the presence of active VitD (calcitriol), LEC tube formation and proliferation were attenuated whilst 
apoptosis was induced in vitro. VDR knock-down in LECs reversed the inhibitory effect of calcitriol on LEC tube 
formation, confirming that this effect is VDR-dependent. In vivo, paricalcitol treatment significantly decreased 
lymphangiogenesis in the kidneys of adriamycin-induced proteinuric rats. This inhibitory effect of VitD may 
Figure 2. Calcitriol blocks LEC tube formation in vitro. LECs were seeded into angiogenesis slides incubated 
with indicated calcitriol concentrations for 4 hours. (a) Representative images (10x magnification) of tube 
formation by LECs treated with different calcitriol concentrations. (b) The total tube length and (c) number of 
branching points of 5 high power fields per condition was quantified and normalized against the vehicle control. 
The data are expressed as the mean ± SEM from three independent experiments. *P < 0.01 compared to the 
control (vehicle) group, ¤P < 0.01 compared to 0.1 nM.
www.nature.com/scientificreports/
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Figure 3. siRNA for VDR sufficiently knocks down VDR expression in cultured LECs. LECs were 
transfected with siRNA for VDR (siRNA 1 and siRNA 2) and scrambled siRNA. (a) mRNA expression of VDR 
measured at 48 h after transfection. siRNA 1 and 2 largely abolished VDR mRNA expression compared with 
scrambled siRNA transfection. (b) Photomicrographs of immunofluorescence for VDR (mouse anti-VDR 
D6) 48 h after siRNA transfection. The staining showed that VDR expression was not affected in scramble-
transfected cells (compared with medium), whereas VDR expression was virtually absent in siRNA VDR-
transfected LECs (400x). Scale bar: 50 μ m.
www.nature.com/scientificreports/
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have important clinical implications in disease conditions which exhibit excessive or inappropriate as well as 
detrimental lymphangiogenesis.
Numerous studies have highlighted the fundamental role of lymphatic vessels and lymphangiogenesis in phys-
iological and pathological conditions1–3. Both blocking and promoting lymphangiogenesis have been suggested to 
be advantageous, and therefore imply to be highly context-dependent. For example, inducing lymphangiogenesis 
has been shown to decrease interstitial fluid accumulation in experimental models of lymphedema36,37, and also 
reported to be of advantage in the resolution of inflammation11,12,38. A recent study by Chi et al.39 showed that 
promoting lymphangiogenesis by VEGF-C156S increased clearance of interstitial hyaluronan (HA), and could 
improve graft outcomes in an animal model of lung transplantation. Contrary to these findings, inhibiting lym-
phangiogenesis in several experimental transplantation models improved graft survival6–10. Whether lymphangi-
ogenesis is a ‘friend or foe’ in kidney transplantation, is still unclear4. Lymphangiogenesis has also sparked a great 
deal of interest in cancer therapy. Numerous studies have demonstrated the feasibility of anti-lymphangiogenic 
therapy to prevent tumor metastasis1–3,16,40. Nevertheless, despite the long history of research on the mechanism 
of lymphangiogenesis and encouraging experimental results, clinically approved anti-lymphangiogenic drugs are 
still not available.
VitD has become a focus of intense interest both because of its vital roles in health, but also as an impor-
tant immune modulator. The beneficial therapeutic effects of VitD and VitD analogues have been proposed in 
many conditions, ranging from proteinuria, fibrosis, atherosclerosis and inflammation to cancer therapy28–33,41. 
It has been found that VDR regulates at least 229 genes through binding to 2776 genomic DNA binding sites. 
Figure 4. The inhibitory effect of calcitriol on tube formation is VDR-dependent. LECs without siRNA-
transfection (no transfection), LECs with scramble siRNA-transfection, and with VDR siRNA-transfection 
(siRNA 1 and siRNA 2) were seeded into angiogenesis and treated with 100 nM calcitriol or PBS for 4 h. (a) 
Representative images (10x magnification) of tube formation. (b) Total length of tube-like structures and (c) 
number of branching points quantified in 5 high power fields and normalized against non-transfected, vehicle 
(no calcitriol)-treated LECs. Data are expressed as the mean ± SEM from three independent experiments. 
*P < 0.05 when compared to the non-transfected and vehicle treated control group.
www.nature.com/scientificreports/
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These genes target anti-proliferative, pro-apoptotic, anti-inflammatory, angiostatic, immune regulatory and 
pro-differentiation functions, and affect many cell functions in tissue- and cell-specific manners41.
Here we demonstrated the expression of VDR in mouse LECs in vitro, both at the mRNA and protein expres-
sion levels. Consistent with these findings, the inhibitory effect of LEC tube formation was completely blocked 
after gene knock-down of VDR in LECs, highlighting the dependence of functional VDR in mouse LECs for 
reduced lymphangiogenesis. Taken together, these experimental findings shown that calcitriol blocks LEC tube 
formation in a VDR-dependent manner. Blood endothelial cells also express VDR22, and active VitD has been 
shown to induce both angiogenic and anti-angiogenic effects on blood endothelial cells24–27,42–45. The effect of 
VitD on blood endothelial cell proliferation is also contradictory. Calcitriol has been shown to inhibit the prolif-
eration of human umbilical vein endothelial cells (HUVEC)46, while another report found an induction of prolif-
eration through a nitric oxide-dependent mechanism in the same cell type26. These inconsistencies might reflect 
differences in treatment concentrations or origin of cells/tissues that were used.
The effect of calcitriol on LEC proliferation and apoptosis was studied in order to gain additional insights 
into mechanisms underlying the VitD-mediated suppression of LEC tube formation. Our results showed a 
concentration-dependent effect of calcitriol on LEC proliferation. While the lower concentrations promoted pro-
liferation, the highest used concentration significantly prevented this increase of proliferation. Such a biphasic 
effect of the VitD on proliferation has also been reported in mouse epidermal keratinocytes47,48 where low con-
centrations of VitD promoted proliferation while higher concentration (10–1000 nM) inhibited proliferation. 
This result may provide important information regarding physiological and pharmacological actions of VitD, 
respectively. The same calcitriol concentration (100 nM) also significantly blocked LEC tube formation, which 
Figure 5. Calcitriol (100 nM) inhibits LEC proliferation and induces apoptosis. (a) LECs were plated in 
96-well gelatin-coated plates (2,000 cell per well) and treated with PBS or indicated concentrations of calcitriol 
for 24 h or 48 h. Cell proliferation was quantified using the cell proliferation reagent WST-1 during the last 3 h 
of cell culture. Bars represent mean absorbance at 450 nm ± SEM of three independent experiments. Note that 
low doses (0.1–10 nM) of calcitriol promoted, while high doses (100 nM) inhibited proliferation. *P < 0.05 
compared to the vehicle treatment, #P < 0.05 compared with 1 nM calcitriol. (b) Apoptosis was analyzed by 
flow cytometry. LECs were treated with 100 nM calcitriol for 6 h and subsequently stained with anti-Annexin 
V and 7AAD. Apoptotic cells are Annexin V+ 7AAD−. Representative dot plots are depicted. (c) Quantitative 
analysis of five independent experiments. The data are expressed as the mean frequency of Annexin V+ 7AAD− 
cells ± SEM. *P < 0.05.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:44403 | DOI: 10.1038/srep44403
may explain, at least in part, the underlying mechanism(s). One might argue that the high (100 nM) VitD might 
have toxic effects and therefore impairs tube formation and proliferation, and promotes apoptosis. This is how-
ever unlikely since VDR-knock down fully restored tube formation even in the presence of 100 nM calcitriol.
Programmed cell-death or apoptosis, a key mechanism in cancer therapy, can be also induced by VitD through 
repressing the expression of anti-apoptotic proteins such as Bcl2 and Bcl-X, as well as by inducing the expression 
of pro-apoptotic proteins such as BAX, BAD, and BAK49–52. Although in current study we did not delve deeply 
into detailed mechanisms of apoptosis, we did find that calcitriol significantly induced apoptosis in LECs, which 
might be another reason for capillary tube suppression in the presence of calcitriol.
Moreover, treatment with the VitD analogue paricalcitol in the in vivo proteinuric adriamycin-induced 
nephrosis model significantly blocked development of renal lymphangiogenesis compared to vehicle-treated rats. 
Paricalcitol is a synthetic VitD2 agonist of the VDR, and is considered a selective VDR activator53,54. Although 
the affinity of paricalcitol for the VDR is reported to be about three times less than that of calcitriol, calcemic and 
phosphatemic effects of paricalcitol are 10 times lower55. Consequently, we preferred to use paricalcitol which 
has more selective VDR activity and lower risk of side effects such as increase in calcium concentrations or 
hypercalcemia (in very high concentrations). Our in vivo observations are again consistent with our data on the 
inhibitory effect of calcitriol in vitro.
In summary, in this work we show for the first time the expression of VDR by lymphatic endothelial cells. Our 
observations provide further information that calcitriol-induced inhibition of LEC tube formation may reflect 
the anti-proliferative and pro-apoptotic effects of VitD in this model. More in depth and mechanistic studies are 
still required to elucidate the molecular mechanisms responsible for the observed inhibitory effects of VitD on 
LECs. In keeping with our in vitro observations, we also showed the anti-lymphangiogenic effect of paricalcitol 
in the adriamycin-induced nephrosis rat model. These findings describe potentially important novel therapeutic 
effects of VitD since blocking lymphangiogenesis could be useful in treating conditions exhibiting detrimental, 
unfavorable lymphangiogenesis.
Figure 6. Paricalcitol prevents renal lymphangiogenesis in proteinuric rats. (a) At week 12, compared to 
healthy non-proteinuric control rats, the kidneys of proteinuric rats showed a marked increase in the number 
of lymphatic vessels. Representative sections are depicted; arrows point to LVs (all 200x). Scale bar: 100 μ m. (b) 
Paricalcitol treatment significantly prevented renal lymphangiogenesis. Quantification of the lymphatic vessels 
number in cortical area of healthy non-proteinuric, vehicle-treated and paricalcitol-treated proteinuric rat 
kidneys. Bars represent mean LV number/cortical field ± SEM. *P < 0.05.
www.nature.com/scientificreports/
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Materials and Methods
Cell lines and cultures. Murine lymphatic endothelial cells (LECs) were originally derived from mesenteric 
adventitial tissue isolated from transgenic mice expressing a temperature-sensitive SV40 large T antigen (H-2Kb-
tsA58 mice)35. LECs were grown in gelatin-coated flasks using high glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM, Cat. No. BE12-709E, Lonza, Belgium) supplemented with 10% FBS, 4 mM glutamine (Cat. No. 25030, 
Invitrogen-Gibco, Bleiswijk, The Netherlands), and penicillin/streptomycin (Penicillin 50 U/ml/Streptomycin 
50 μ g/ml, Cat. No. 15070-063, Invitrogen-Gibco, Bleiswijk, The Netherlands) at 37 °C and 5% CO2. Mouse tubu-
lar epithelial cells (MTCs)36 were grown in high glucose DMEM supplemented with 10% FBS, 25 mM Hepes 
(Cat. No. 15630, Invitrogen-Gibco), 50 μ g/mL penicillin/streptomycin, and 2 mM glutamine at 37 °C and 5% CO2.
mRNA isolation and qRT-PCR analysis. Total RNA was extracted from MTCs and LECs using RNeasy 
Micro kit (Qiagen, The Netherlands). RNA concentrations were measured with a Nano Drop spectrophotometer 
(NanoDrop Technologies, Wilminton, DE, USA). For MTCs, cDNA was synthesized using QuantiTect Reverse 
Transcriptase Kit (Qiagen, The Netherlands) according to the manufacturer’s guidelines. For LECs cDNA syn-
thesis, 1 μ g RNA was converted to cDNA using SuperScript II reverse transcriptase and random hexamers (Life 
Technologies) according to the manufacturer’s instructions. PCR reactions were executed in a 10 μ l reaction vol-
ume containing 1× Taqman Gene Expression Assay mix (Applied Biosystems, Foster City, USA) and 1× qPCR 
master mix (Eurogentec, Liege, Belgium). The Taqman primers were as follows: YWHAZ Mm03950126_s1 
(Applied Biosystems, Carlsbad, USA) and VDR Mm00437297_m1 (Applied Biosystems, Carlsbad, USA). For 
qRT-PCR reactions, an ABI7900HT thermal cycler (Applied Biosystems, Foster City, CA, USA) was used. 
YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein ζ ) was used as house-
keeping gene, and relative gene expression was calculated using the 2−ΔΔCt method.
Western blotting. To determine VDR expression in MTCs and LECs at the protein level, western blot-
ting was performed. Cells were washed with the Tris-buffered saline (TBS, 20 mM Tris, pH 7.5, 150 mM NaCl) 
and homogenized in Radio immunoprecipitation assay buffer (50 mM Tris–HCl, 150 mM NaCl, 0.1% SDS, 0.1% 
Igepal in 0.5% sodium deoxycholate with 1 tablet of protease inhibitor cocktail and 1 tablet of phosphatase inhibi-
tor; Roche Diagnostics, Mannheim, Germany). The lysates were mixed with loading buffer to make a total volume 
of 20 μ l. Samples were then spun down, boiled at 100 °C for 5 min in a thermo block, spun down again and put on 
ice. 20 μ l of every sample was loaded on a denaturizing 7.5% polyacrylamide gel. On every gel, a protein ladder 
was included to indicate band size. The gel was run for 15 min at 40 V and 75 min at 120 V. After running, the gel 
was soaked for 10 minutes in blotting buffer. The gel was then transferred on a nitrocellulose membrane followed 
by blotting at 150 mA for 45 min. Afterwards the membrane was blocked with TBS with 5% milk powder and 
0.1% Tween 20 for 2 h at 4 °C. The membrane was incubated overnight at 4 °C with mouse anti-VDR D6 (1:500) 
(Santa Cruz Biotechnology, Inc) diluted in TBS-T (TBS with 0.1% Tween 20) with 1% milk powder. The mem-
brane was washed twice followed by incubation for 2 h at RT with rabbit anti-mouse Ig horseradish peroxidase 
(HRP) (DAKO, Heverlee, Belgium) diluted 1:1000 in TBS-T with 1% milk powder. The membrane was washed 
twice and HRP activity was visualized with a chemiluminescence kit (NEL103E001EA, PerkinElmer® ) according 
to the manufacturer’s instructions. The chemiluminescence membrane was recorded on an ImageQuant™ LAS 
4000 system.
Immunohistochemistry (IHC) and immunofluorescence (IF). Immunostaining was performed on 
formalin-fixed, paraffin-embedded tissues or acetone-fixed cultured cells/tissues. Three-micron paraffin-sections 
were deparaffinized followed by heat-induced epitope retrieval (HIER) in boiling 10 mM Tris–1 mM EDTA 
buffer (pH 9.0) for 10 min. After cooling, tissue endogenous peroxidase was blocked using 0.3% H2O2 in 
phosphate-buffered saline (PBS). For frozen tissue sections, endogenous peroxidase was blocked using 0.03% 
H2O2 in PBS. Endogenous biotin was inhibited using biotin blocking system (Code X0590, DAKO, Heverlee, 
Belgium). For staining on in vitro cultured LECs, cells were seeded at a density of 5 × 103 cells/ml on glass cover-
slips (Marienfeld laboratory glassware, Lauda-Königshofen, Germany) in 12-well plates overnight. For IHC and 
IF, cells or tissue cryosections were acetone-fixed (10 min. RT) followed by permeabilization in 0.1% Triton-X100 
in PBS at RT. Cells (no endogenous blockade was applied) or tissue sections were then incubated with the follow-
ing primary antibodies for 1 h at RT: hamster anti-mouse podoplanin (Cat. No. DM3501, Acris Antibodies Inc., 
Germany), mouse-anti human podoplanin, clone D2–40 (Code M3619, DAKO, Heverlee, Belgium), rabbit-anti 
human prox-1 (Cat. No. 102-PA32S, ReliaTech GmbH, Germany), mouse anti-rat podoplanin (Cat. No. 11–035, 
Angio Bio, Del Mar, USA), goat anti-mouse VEGFR3 (Cat. No. AF743, R&D system, Inc.), mouse anti-VDR (D-6: 
sc-13133, Santa Cruz Biotechnology, Inc.). Following washing in 0.1% Tween 20 in PBS (PBS-T), cells or tissue 
sections were incubated with appropriate secondary antibodies diluted in PBS + 1% mouse or human serum for 
30 min. The following secondary antibodies (all purchased from DAKO, Heverlee, Belgium) were used: biotiny-
lated rabbit anti-mouse Ig, rabbit anti-mouse Ig horseradish peroxidase (HRP)-conjugated, rabbit anti-mouse 
Ig fluorescein isothiocyanate (FITC)-conjugated, rabbit anti-goat Ig HRP-conjugated, goat anti-rabbit Ig and 
goat-anti mouse Ig (both HRP and FITC-conjugated). The TSATM Tetramethylrhodamine System (10 min, 
PerkinElmer LAS Inc., USA) and FITC-conjugated streptavidin (45 min, Invitrogen) were used to visualize 
HRP-conjugated and biotinylated secondary antibodies, respectively. As a control for non-specific secondary anti-
body binding, PBS + 1% BSA substituted primary antibodies (negative control). 4′ ,6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories, Inc.) was used for nuclear staining. IF was visualized on a Leica fluorescent micro-
scope (DM4000B, equipped with DFC345FX camera and LAS software) or Zeiss confocal microscope (LSM 780 
Axio Observer.Z1, Carl Zeiss Microscopy GmbH, Jena, Germany).
IHC was performed on paraffin sections using the same protocol as described above but HRP-conjugated 
secondary antibodies were diluted in PBS + 1% normal rat serum. HRP-activity was visualized using 3,3′ 
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-diaminobenzidine (DAB, Sigma-Aldrich, USA) as chromogen with hematoxylin counterstaining. Slides were 
scanned on a Nano Zoomer HT whole slide scanner (Hamamatsu Photonics K.K., Shizuoka Pref., Japan) and 
sections were analyzed using Aperio Image Scope software (Aperio Technologies Inc, Vista, CA, USA).
Tube formation assay. Matrigel tube formation assays were performed to investigate lymphangiogenesis 
in vitro. The endothelial cell tube formation assay on basement membrane (including Matrigel) is widely used 
to study angiogenic potential in vitro (reviewed in ref. 56). Although vascular endothelial cells are most com-
monly used in this assay, it has also been described useful to study lymphangiogenesis57. Although not visible 
at the microscopical level, studies performed at the ultrastructural level (i.e. electron microscopy) revealed that 
the tubes formed when using either vascular endothelial cells58 or LECs59 contain a lumen. Based on this data 
the LEC tube formation assay appears to be a suitable model to study lymphangiogenesis in vitro. Here 15-well 
μ -Slide Angiogenesis (Cat. No. 81501, ibidi, Martinsried, Germany) and Growth Factor Reduced Matrigel (Cat. 
No. 356230, BD Biosciences, Bedford, MA) were used. 10 μ L of Matrigel was placed per well and incubated at 
37 °C for 30 minutes. 50 μ L of 1.4 × 105 cells/mL LECs incubated in DMEM were added to each well with or with-
out 1α ,25-Dihydroxyvitamin D3 (calcitriol) (D1530, Sigma Aldrich, USA). Calcitriol was added to the medium 
to reach a final concentration of 0.1 nM, 1 nM, 10 nM or 100 nM (performed in triplicates). Cells were incubated 
for 4 h at 37 °C in humidified air with 5% CO2. Tube formation assay was also performed on VDR knock-down 
cells. No siRNA-transfected, VDR siRNA-transfected and scramble siRNA-transfected LECs were seeded into 
μ -Slide Angiogenesis pre-coated with 10 μ l growth factor-reduced Matrigel. Simultaneously, cells were treated 
with 100 nM calcitriol or PBS. After 4 h incubation the capillary tubes were analyzed. Representative images 
were captured with an Olympus inverted phase-contrast microscope (Olympus Optical C., Melviller, NY, USA) 
equipped with the Quick Imaging System. From each well 5 images were taken (at 100 x magnification) at fixed 
areas (starting at the center of the well and then above, below, right, left of the center). To perform quantifications, 
both the total cumulative tube length (i.e. total cumulative length of all tubes visible in the photomicrographs) 
and the total number of branching points were determined in all 5 pictures per well and corrected by the image 
surface using Image J 1.46r software (Rasband, W.S., U.S. National Institutes of Health). Then the average of the 
3 wells values per group was calculated. Results were normalized to the data of the vehicle-treated group (PBS). 
Three independent experiments were performed.
siRNA transfection. To determine the efficacy of siRNA knock-down on VDR mRNA and protein expres-
sion levels in LECs, knock-down cells were analyzed at 48 h. Commercially available VDR siRNA (s75929 and 
s75930, Life Technologies, Bleiswijk, The Netherlands) and Silencer® Select scramble siRNA (Cat. No. 4390843, 
Life Technologies) were used. As additional controls, untreated cells (medium only) and cells treated with only 
Lipofectamine® Transfection Reagent (Cat. No. 11668-019, Life Technologies) without siRNAs were used. 
5 nmole siRNA was diluted in RNase-free water to a final concentration of 2.5 μ M. Transfections were performed 
in 12-well plates by adding 200 μ l of Opti-MEM reduced serum medium and 4.8 μ l of 2.5 μ M siRNA/well. Next, 
2 μ l/well of lipofectamine was added and incubated for 10–20 min at RT. 1 ml of cells/medium was added per well 
(10 nM siRNA concentration) and incubated for 48 h at 37 °C, 5% CO2. All transfections were performed on LECs 
that had been cultured in antibiotics-free complete LEC medium. All experiments were performed 48 hours after 
transfection.
Proliferation assay. The effect of 1α ,25-Dihydroxyvitamin D3 (calcitriol) (D1530, Sigma Aldrich, USA) 
on proliferation of LECs was determined by plating cells in 96-well gelatin-coated plates (2,000 cells per well) in 
200 μ l medium. The cells were incubated at 37 °C for 3.5 hours for adherence and then treated with vehicle (PBS) 
or various concentrations of calcitriol for 24 h or 48 h. For cells cultured for 48 h (with or without calcitriol), 
medium was replenished with new medium containing the appropriate calcitriol concentration after 24 h. Cell 
proliferation was quantified using Cell Proliferation Reagent WST-1 (100 μ l/well) according to the manufacturer’s 
instructions and absorption was measured after three hours of WST-1 incubation.
Apoptosis assay. LECs were plated in 6-well culture plates in DMEM at a density of 1.5 × 105 cells/ml. Cells 
were allowed to attach for 24 h, starved for additional 24 h and subsequently stimulated with 100 nM calcitriol for 
6 h. Non-stimulated cells (no calcitriol, medium only) served as negative control. A positive control for the stain-
ing procedure was obtained by addition of 0.4 mM H2O2 to LECs for 6 h to induce cell death. Cells were trypsin-
ized, washed in PBS twice and stained with anti-Annexin V Apoptosis Detection Kit and 7-AAD (Cat: 640922, 
Uithoorn, The Netherlands) according the supplier’s protocol. Fluorescence was assessed on a FACS Calibur flow 
cytometer (BD Bioscience, Breda, The Netherlands) within the same day. At least 10,000 gated events were col-
lected per sample and data was analyzed using Flowjo software (Tree Star, Inc., Ashland, OR, USA).
Induction of proteinuria in rats. Adriamycin Nephrosis (AN) was induced in Wistar rats (Harlan, The 
Netherlands) by a single injection of 1.5 mg/kg adriamycin (Doxorubicin® ) into the tail vein as previously 
described37. After 6 weeks animals were placed in 24-hour metabolic cages for urine collection, and then rats 
were stratified according to the level of proteinuria into two experimental groups. Subsequently, at six weeks after 
adriamycin injection, renal biopsy was taken via abdominal incision in order to evaluate kidney histology and 
numbers of LVs. Animals were treated then with paricalcitol 160 ng/kg three times per week p.o. (paricalcitol/
ethanol dissolved in water, n = 8) or vehicle (ethanol diluted in water, n = 6) from week 6 to 12. At the end of the 
study, blood and kidneys were collected for further analysis. All animals received care in compliance with the 
recommendations of ARRIVE, the Directive 2010/63/EU and the Dutch Law on Experimental Animal Care, and 
were approved by the animal ethics committee of the University of Groningen.
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Quantification lymphatic vessel density. In order to evaluate lymphangiogenesis in rat kidneys, 
podoplanin-stained kidney sections were scanned on a NanoZoomer HT machine (Hamamatsu Photonics K.K., 
Shizuoka Pref., Japan). After scanning, the number of podoplanin-positive vessels present in 30 cortical tubu-
lointerstitial fields per kidney was manually counted using Aperio ImageScope software (version 9.1.772.1570, 
Aperio Technologies Inc, Vista, CA, USA) and Image J 1.46r software (Rasband, W.S., U.S. National Institutes of 
Health). The results are expressed as mean number of lymphatic vessels per cortical tubulointerstitial field ± SEM.
Statistics. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, 
CA). Data are expressed as mean ± standard error of the mean (SEM). Differences between multiple groups 
were calculated using ANOVA (Bonferroni post-hoc test) with p < 0.05 as the minimal level of significance. 
Comparisons of two groups were performed using Mann-Whitney U-test.
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